SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01585948

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Role of Newer and Traditional Risk Factors in the Development, Extent and Manifestation of Coronary Artery Disease

In the present study the investigators will measure the extent of coronary artery disease via coronary angiography and the correlating risk factors.

NCT01585948 Patients Undergoing Coronary Angiography
MeSH: Coronary Artery Disease Myocardial Ischemia Coronary Disease
HPO: Coronary artery atherosclerosis


Primary Outcomes

Description: We will investigate the incidence, extent and clinical manifestation of coronary artery disease in diabetics and non-diabetics undergoing coronary angiography for clinical reasons.

Measure: The incidence and extent of coronary artery disease between diabetics and non-diabetic patients.

Time: Up to four years on average.

Secondary Outcomes

Description: To associate the incidence, extent and clinical manifestation of coronary artery disease with classic demographic risk factors (such as smoking, alcohol consumption, physical exercise, arterial hypertension, family history of diabetes mellitus or coronary artery disease) and common biochemical risk factors (such as fasting glucose levels, urea, creatinine, HbA1c%, uric acid, total cholesterol, HDL, LDL, triglycerides, VLDL, glomerular filtration rate - GFR).

Measure: The incidence and extent of coronary artery disease via coronary angiography scores and related biochemical and demographical risk factors.

Time: Up to 4 years on average.

Description: To associate the incidence, extent and clinical manifestation of coronary artery disease with systemic inflammatory status assessed by hs-CRP levels, circulating adipokines (adiponectin, resistin) and the receptors of advanced glycation end products (sRAGE and esRAGE).

Measure: The incidence, extent and clinical manifestation of coronary artery disease and the circulating levels of hs-CRP, adipokines and RAGEs.

Time: Up to 4 years on average.

Description: To associate the incidence, extent and clinical manifestation of coronary artery disease with the rs7903146 single nucleotide polymorphism of TCF7L2 gene, that has been strongly associated with diabetes mellitus development.

Measure: TCF7L2 gene polymorphims and the incidence and extent of coronary artery disease.

Time: Within a maximum period of 4 years.

Time Perspective: Cross-Sectional

Case-Control


There is one SNP

SNPs


1 rs7903146

The incidence, extent and clinical manifestation of coronary artery disease and the circulating levels of hs-CRP, adipokines and RAGEs.. To associate the incidence, extent and clinical manifestation of coronary artery disease with systemic inflammatory status assessed by hs-CRP levels, circulating adipokines (adiponectin, resistin) and the receptors of advanced glycation end products (sRAGE and esRAGE).. TCF7L2 gene polymorphims and the incidence and extent of coronary artery disease.. To associate the incidence, extent and clinical manifestation of coronary artery disease with the rs7903146 single nucleotide polymorphism of TCF7L2 gene, that has been strongly associated with diabetes mellitus development.. Inclusion Criteria: - Any subject eligible for coronary angiography with or without known CV disease for clinical reasons.



HPO Nodes


HPO:
Coronary artery atherosclerosis
Genes 48
LMNA LDLRAP1 LDLR ACTA2 CYP7A1 FBN1 APOE APOB ESR1 MAT2A ABCA1 KCNJ5 ABCG8 MYH11 ZNF687 TGFB2 LMNA LMNA ELN LMNA LIPC PPARG LMNA FOXE3 SERPIND1 SMAD4 TGFBR2 SMPD1 MFAP5 ABCA1 APOB LMNA LOX SMAD3 MYH11 MYH11 LOX LMNA PCSK9 ACTA2 ABCG8 ZMPSTE24 TGFB3 PRKG1 TGFBR1 MYLK CEP19 ABCG5